Objective: Adverse cardiac events in patients treated with the phosphodiesterase-5 inhibitor sildenafil for erectile dysfunction raised concerns about its safety in ischemic heart disease. Methods: In anesthetized open-chest rabbits, receiving 1.45 mg / kg sildenafil intravenously or saline 30 min prior to ischemia (n512, each), infarct size (IS, triphenyltetrazolium), the area of no-reflow (ANR, thioflavin S) (% of the risk area, RA, blue dye), and regional myocardial blood flow (RMBF, radioactive microspheres) were measured after 30 min of coronary occlusion and 180 min of reperfusion. Left ventricular hemodynamics and dimensions (echocardiography) were determined in a separate series of animals (n55, each). Results: Sildenafil significantly lowered arterial blood pressure before occlusion (217 to 219 mmHg over 30 min), but during ischemia and reperfusion hemodynamics were comparable to controls. IS in treated animals (5164%) did not significantly differ from control animals (4764%). No major arrhythmias or lengthening of QT / QTc occurred. While sildenafil slightly increased RMBF and significantly reduced specific vascular resistance in the RA during reperfusion (5167 versus 73610 mmHg g min / ml, P,0.05), the ANR (4663%) was similar to control animals (4464%). Sildenafil reduced left ventricular dP/dt (P,0.05) and dP/dt (P,0.01) in non-ischemic conditions, and slightly during ischemia, along with a pronounced decrease in max min ischemic left ventricular end-diastolic pressure (962 versus 1562 mmHg after saline, P,0.05), but did not attenuate acute ischemic left ventricular dilation. Conclusions: Sildenafil reduced cardiac pre-and afterload, and parameters of left ventricular contractility. Myocardial necrosis and microvascular dysfunction were neither exacerbated nor attenuated.
. Introduction
trials and retrospective analyses [5, 6] . Since patients with erectile dysfunction share most of the risk factors with Sildenafil, the first oral agent approved for treatment of patients suffering from ischemic heart disease [7] , and on erectile dysfunction, is a selective inhibitor of the isoform the other hand sexual activity might bear a slightly 5 of the enzyme phosphodiesterase, which is responsible increased risk for a cardiac event [8] , detrimental side for the breakdown of 39,59-cyclic guanosine monophoseffects of sildenafil in myocardial ischemia would be of phate (cGMP) in smooth muscle cells of the corpora utmost importance. Furthermore, recent investigations cavernosa, and systemic and pulmonary vasculature [1] .
reported benefits of sildenafil in pulmonary arterial hySoon after the approval of sildenafil, several reports of pertension [9] , and in congestive heart failure [10]; again cardiac events among men treated with sildenafil raised two conditions that are frequently associated with coronary some concern about its safety in patients with coronary artery disease. artery disease [2] [3] [4] . However, these spontaneous reports Among others, three basic concepts could theoretically of adverse events did not find their correlate in randomized explain accelerated myocardial necrosis during ischemia or a decreased threshold for arrhythmias: firstly, Phillips et al. described that treatment with sildenafil in healthy vol-unteers was accompanied by sympathetic activation [11] ; 2 .2. Protocol 1 secondly, experimental studies reported a prolongation of the cardiac action potential under sildenafil [12] ; and A catheter was inserted into the left atrial appendage. thirdly, elevated concentrations of cGMP could theoretAfter baseline hemodynamics, 1.45 mg / kg sildenafil (1 g / l ically result in increased levels of myocardial 39,59-cyclic sildenafil as pure powder in saline, pH 2.7) or 1 ml / kg adenosine monophosphate (cAMP), the breakdown of 0.9% saline (pH 2.7) was administered intravenously in a which is dependent on hydrolysis by the phosphodiesterase randomized fashion over |5 min (n512, each). Thirty isoform 3, which can be inhibited by cGMP [13] [14] [15] .
minutes later, the snare around the coronary artery was On the other hand, sildenafil, as a venous and arterial tightened for 30 min. Then, reperfusion was allowed for vasodilator, might reduce cardiac pre-and afterload, which 180 min. Regional myocardial blood flow (RMBF) was could attenuate acute ischemic left ventricular dilation. In measured at 25 min of ischemia, and at 170 min of addition, sildenafil was shown to increase coronary flow reperfusion. reserve in patients [16] . As initial concerns about a potential coronary steal effect under sildenafil, shifting blood flow from the ischemic territory towards non-2 .2.1. Infarct size (IS), risk area (RA) and area of noischemic myocardial tissue, were not supported by exreflow (ANR) perimental investigations [17, 18] , vasodilating properties At the end of the protocol, 1 ml / kg 4% thioflavin S of sildenafil might also be beneficial.
(Sigma, St. Louis, MO, USA; dissolved in 0.9% saline, Therefore, we investigated whether sildenafil might then centrifuged (1500 rev. / min) for 5 min) was injected exacerbate or attenuate myocardial necrosis and miinto the left atrium. Thioflavin S is a vital fluorescent stain crovascular dysfunction in experimental ischemia and for endothelium. To delineate the risk area (RA), the reperfusion.
coronary artery was re-occluded, and 4 ml 50% Uniperse blue (Ciba Geigy, Hawthorne, NY, USA) was injected into the left atrium. The rabbit was euthanized by an intravenous overdose of xylazine (100 mg i.v.) and 12 mEq KCl 2 . Methods (intraatrial). The left ventricle was sliced into 6-7 transverse sections, photographed under water, re-photographed The rationale was to investigate cardiovascular effects of under ultraviolet light (365 nm wavelength, Spectroline sildenafil in experimental myocardial ischemia and reModel ENF 280 C, Spectronics, Westbury, NY, USA) perfusion. The experiments were conducted in accordance using a Y48 barrier filter (Minolta), and again photowith the national and institutional Guide for the Care and graphed after incubation in 1% triphenyltetrazolium chloUse of Laboratory Animals. Good Samaritan Hospital's ride (37 8C, 15 min). Triphenyltetrazolium chloride stains Heart Institute is an AAALAC-accredited organisation.
viable myocardium red. The contour of each slice, the RA, not stained by the blue dye, the area of no-reflow (ANR), defined as the non-fluorescent area within the risk zone, 2 .1. Animal preparation and infarct size (IS), not stained by triphenyltetrazolium chloride, were traced manually from projected New Zealand White male rabbits (2.0-3.0 kg) were slides and planimetered. The RA was expressed as a anesthetized by intramuscular ketamine (400 mg) and percentage of the weight of the left ventricle, the ANR and xylazine (200 mg). After tracheotomy, and initiation of IS as a percentage of the weight of the RA. As demonventilation (35 breaths / min, 15 ml tidal volume, adjusted strated in previous investigations, this experimental model after opening of the chest, Harvard Respirator, Model 665, does not result in myocardial necrosis or areas of no reflow 1.5 l / min oxygen) catheters were inserted into the right without coronary occlusion [19] . jugular vein for additional anesthesia (pentobarbital, as needed), sildenafil or saline, and into the right carotid artery. coronary artery was encircled by a suture (4-0 silk suture, labeled with Cerium or Ruthenium, were injected Ethicon, Sommerville, NJ, USA). The two ends of the into the left atrium and simultaneously an arterial reference suture were threaded through a length of plastic tubing, blood sample (2.06 ml / min) was withdrawn. Radioactivity forming a snare, which could be tightened. Body temperawas counted in the tissue stained by the blue dye (nonture was maintained by a heating pad under continuous ischemic tissue) and not stained by the dye (tissue at risk) monitoring of rectal temperature. An ECG was recorded in a multi-channel pulse-height analyzer (model ND62, throughout the protocol. After the surgical procedure, Nuclear Data Schaumburg, IL, USA). RMBF was calcuanimals were allowed to stabilize for 15 min. lated after correction for background and crossover as the ratio of counts in the tissue and the reference blood sample randomized fashion after the 15-min recording (n55, multiplied by 2.06 ml / min and divided by the weight of each). the tissue sample.
Before measuring RMBF, the central venous pressure 2 .5. Statistical analyses was measured from the jugular catheter, and specific vascular resistance calculated as (mean arterial blood
Animals showing a RA of less than 20%, animals that pressure2central venous pressure) / RMBF (units: mmHg3
did not survive, and in protocol 1, hearts with a regional g3min / ml).
myocardial blood flow of more than 0.2 ml/g/min within the RA during occlusion were excluded and replaced. were recorded (sampling rate 1 k / s) and averaged over (ANR), and regional myocardial blood flow (RMBF) three consecutive cycles at baseline, 15 and 30 min after coronary occlusion before the animal was euthanized. At 3 .1.1. Exclusions 15 min of occlusion, animals received sildenafil (1.45 One animal with a risk area of less than 20% of the left mg / kg) or saline (n55, each) in a randomized fashion.
ventricle (sildenafil group), and two animals in the saline QT-duration was measured from an electrocardiographic group (one animal with a regional myocardial blood flow chest lead, positioned adjacent to the apex of the heart, and of 0.76 ml/g/min in the risk area during occlusion, and averaged over three beats. QTc was calculated according to one animal died during reperfusion from hypotension) Bazett's formula as QT / [sqrt(60 / heart rate)].
were excluded from the analysis and replaced. Presented data are based on 12 animals in each group.
2 .3.2. Protocol 2b 3 .1.2. Hemodynamics ( Fig. 1 ) In a non-randomized set of four animals, left ventricular Application of 1.45 mg / kg sildenafil resulted in a hemodynamics were measured at baseline and 15 min after moderate, but significant decrease of systolic and diastolic administration of sildenafil without coronary occlusion.
blood pressure (over 30 min, systolic and diastolic blood pressure: 217 to 219 mmHg versus baseline). During coronary occlusion, blood pressure further declined in both 2 .4. Protocol 3 groups, but systolic blood pressure in the sildenafil group was only slightly lower compared with control (maximal: After surgery, the chest was closed by two sutures with 23 mmHg). For the rest of the protocol, differences in the snare around the coronary artery not tightened. Twoblood pressure between the two groups were minimal; and dimensional echocardiographic images of the left ventricle heart rate, albeit slightly increasing after sildenafil, was not on a short axis view at the midpapillary level were significantly different between the groups. Importantly, the recorded, using a 7.5 MHz transducer, connected to an heart rate-mean arterial blood pressure product during echocardiographic imaging unit (Hewlett Packard, Sonos coronary occlusion was not significantly different (at 30 1000 Ultrasound System). Diastolic and systolic left venmin of occlusion: 12,2626741 mmHg / min in saline tricular areas (LV-area) were planimetered and averaged animals versus 13,2406466 mmHg / min in the sildenafil over three consecutive cycles at baseline, 15 and 30 min group). No major arrhythmias occurred in either group, after coronary artery occlusion before euthanizing the except for a few self-limiting ventricular arrhythmias rabbit. Saline or 1.45 mg / kg sildenafil were then given in a ( Table 1) . Fig. 1 . Body temperature, heart rate, and systolic and diastolic blood pressure in the control group (left, n512) and sildenafil treatment group (right, n512) in the course of protocol 1. Statistical comparison by two-way ANOVA (included data points: baseline, pre-occlusion, 30 min of occlusion, 170 min of reperfusion) revealed no differences for heart rate and body temperature, and for blood pressure data a significant (P,0.01) time-related effect, and interaction effect (P,0.01). *P,0.05, **P,0.01 for post-hoc comparisons between corresponding time points in the two groups.
3 .1.3. Risk area, infarct size, and area of no-reflow 3 .1.4. Regional myocardial blood flow (RMBF), and (Fig. 2) specific vascular resistance (Figs. 3 and 4 ) The RA was similar in the two groups (Fig. 2) . IS RMBF and vascular resistance in the RA during coramounted to 4764% in the control group and 5164% in onary occlusion were not significantly different between the sildenafil group (not significant). Concomitantly, the the two groups (Fig. 3) . In the treated group, RMBF values ANR was 4464% in the saline group and 4663% in the were slightly higher without reaching statistical signifitreated group (not significant). Infarct size and ANR cance. At 170 min of reperfusion, vascular resistance demonstrated a close spatial concordance, and their size within the RA was significantly lower in the sildenafil was significantly correlated with each other in both groups group (P,0.05). RMBF within the RA, expressed as a (r50.72-0.85). Comparison of the relationship between IS percentage of non-ischemic flow, was inversely correlated and ANR by ANCOVA with IS as a covariate did not with IS (Fig. 4) . Comparison of the relationship between reveal a significant difference (adjusted means for ANR:
both parameters by ANCOVA with IS as a covariate did control group 46%, sildenafil group 44%). not demonstrate a significant difference. animals (n512) and animals treated with sildenafil (n512) (protocol 1)
They were replaced, and presented data are derived from (sign., significant).
five animals in each group.
.2.3.2. Left ventricular dimensions In both groups, cor-.2. Protocol 2. Left ventricular hemodynamics and QT-
onary occlusion led to a significant increase in diastolic duration and systolic left ventricular areas, as measured by twodimensional echocardiography (Fig. 6) . The values mea-3 .2.1. Protocol 2a sured after 15 min of occlusion remained relatively stable, and no significant changes were observed after the applica-3 .2.1.1. Exclusions Two animals died during occlusion tion of sildenafil. Statistical comparison revealed a timebefore the administration of saline or sildenafil (one from related effect due to the increase of dimension during hypotension, one from ventricular fibrillation). They were coronary occlusion without interaction. replaced, and presented data are based on five animals in each group. According to Walker et al., pharmacology of sildenafil in kg body weight, as a single oral dose in patients to achieve both men and rabbits is similar, including an identical concentrations similar to the upper range in patients treated volume of distribution (1-2 l / kg) and only slightly longer for erectile dysfunction. half life in men [20] . While in young healthy volunteers, In this study 1.45 mg / kg sildenafil resulted in significant oral bioavailability was limited by a hepatic first pass reduction of systolic and diastolic blood pressure, confirmeffect and amounted to |40% [21] , these values were ing the pharmacologic efficacy in this model. The moderdoubled in the elderly [22] and further increased in patients ate blood pressure lowering effect, the reduction of dP/ with hepatic dysfunction [22] . Therefore, we chose an dt and dP/dt , and the attenuation of LVEDP by max min intravenous dose of 1.45 mg / kg, parallel to 100 mg per 70 sildenafil did not transfer into detectable attenuation of acute ischemic left ventricular dilation, as assessed by two-dimensional echocardiography. Concomitantly, infarct size was not reduced nor was myocardial necrosis exacerbated by sildenafil treatment. Albeit slightly improving RMBF and reducing specific vascular resistance in the RA during reperfusion, sildenafil did not reduce anatomic no-reflow, which remained closely associated with myocardial necrosis. No major arrhythmias occurred with sildenafil during occlusion, and the QTcduration was not lengthened.
.1. Sildenafil and myocardial necrosis in ischemiareperfusion
Our results contrast with a recent study by Ockaili et al., performed in a very similar rabbit model [23] , that described pronounced infarct size-reducing effects of min after coronary occlusion, and after application of intravenous sildenafil (n55) or saline (n55) during occlusion (protocol 2). Two-way ANOVA revealed a time-related effect (P,0.05 for dP/dt , P,0.01 for dP/dt ) due to the decrease after coronary occlusion without interaction or group effects.
max min
Lower panel, left ventricular end-diastolic pressure (LVEDP) under baseline conditions, 15 min after coronary occlusion and after administration of saline or sildenafil during ischemia (protocol 2). LVEDP after sildenafil was significantly lower than after saline administration. Comparison by two-way ANOVA showed a significant time-related effect (P,0.01) due to the rise in LVEDP during ischemia (*P,0.05 versus control). Fig. 6 . Left ventricular cross sectional area (LV-area) on the mid-papillary level, as assessed by two-dimensional echocardiography at baseline, 15 min after coronary occlusion, and 15 min after application of saline or sildenafil (protocol 3). Two-way ANOVA revealed a significant time-related effect due to acute ischemic left ventricular dilation without significant changes after sildenafil treatment or interaction effects.
rest of the study protocol, including anesthesia with hanced calcium transients. But, also action potential-shortketamine / xylazine, appears to be comparable.
ening effects of sildenafil have been described [24] , and We tested whether infarct size in our study correlates the concentrations, needed for the effects reported by with the degree of the initial pressure drop after sildenafil, Gellen et al. were probably above the therapeutical level which might be an indirect measure of the amount of [25] . In the present investigation, we did not observe major cGMP accumulation after sildenafil, or theoretically could arrhythmias with sildenafil treatment; furthermore, silbe interpreted as a potential preconditioning-like stimulus denafil did not lengthen QT or QTc duration during by transiently reducing coronary perfusion. The amount of ischemia. These findings are in accordance with a recent pressure drop correlated positively, but not significantly report in patients with chronic heart failure, that did not with infarct size in our study (r50.47). We tried to avoid find alterations of the QT duration or major arrhythmias major transient hypotension (range of systolic pressure [26] . drop after sildenafil: 25 to 231 mmHg) by slow adminis-A third concern is related to a potential 'cross-talk' tration of sildenafil over |5 min. One might speculate that between cGMP and cAMP [13] . Moderately increased more pronounced transient periods of hypotension might levels of cGMP were shown to inhibit phosphodiesterase be able to activate signal pathways involved in ischemic 3, the enzyme responsible for hydrolysis of cAMP, and preconditioning.
thereby may enhance myocardial contractility as a conseAfter Ockailli's work had been published, we performed quence of higher cAMP levels. However, the presence of additional experiments parallel to protocol 1, in which phosphodiesterase 5 in cardiomyocytes, a prerequisite for pretreatment with 0.7 mg / kg sildenafil was compared with this theoretical cross talk, is controversial: in isolated dog saline treatment (n55, each) in order to investigate trabeculae carneae, stimulated by isoprenaline, sildenafil whether the higher dose used in our study was responsible did not exhibit effects on myocardial contractility in for the different results. In these experiments again, contrast to the selective phosphodiesterase 3 inhibitor sildenafil did not reduce IS (107% of IS in control animals) milrinone [1] , which argued against a significant PDE 5 and ANR (105% of ANR in control animals) ( and cAMP did not seem to be relevant. On the other hand, sildenafil, as a venous and arterial The clinical importance of a variety of cardiovascular vasodilator, might also exhibit beneficial effects in effects after treatment with sildenafil is still a matter of myocardial ischemia by reducing pre-and afterload [29] or debate. A direct translation of this experimental model of by improving coronary perfusion. In the present invesischemia / reperfusion to various clinical conditions might tigations, effects of sildenafil on arterial blood pressure not be possible; however, the results could help to estimate were mild, but LVEDP was markedly reduced during the relevance of some proposed actions of sildenafil.
ischemia. These hemodynamic changes, while potentially As potentially harmful under ischemic conditions, one beneficial, were apparently too small to transfer into might mention three basic concepts. Phillips et al. designificant effects of left ventricular dilation during isscribed a pronounced sympathetic activation in healthy chemia. volunteers after 100 mg oral sildenafil [11] . In the present RMBF, however, demonstrated a tendency of improvestudy, performed in anesthetized animals, heart rate slightment with sildenafil treatment; and specific vascular resistly increased after sildenafil administration, which might be ance in the risk area at the end of the protocol was most likely explained as a response to the lowered blood significantly reduced. However, the size of perfusion pressure. Heart rate-pressure product after sildenafil was defects, the anatomic basis of the no-reflow phenomenon not increased (17, 3406885 mmHg / min at baseline vs.
in reperfused infarcts, was not reduced and remained 14,7396569 mmHg / min 15 min after sildenafil).
closely related to infarct size. As demonstrated by HerGellen et al. demonstrated an inhibitory effect of mann et al. in patients with coronary artery disease [16] , sildenafil on the rapid component of the delayed rectifier sildenafil increased coronary flow in stenosed coronary potassium channel [12] , which in theory could lead to arteries and coronary arteries without a significant stenosis lengthening of action potential duration and in turn into a similar extent; and a coronary steal phenomenon under crease myocardial contractility during ischemia via enthe influence of sildenafil was not supported in animal parison with non-ischemic flow (Fig. 4) .
